BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

955 related articles for article (PubMed ID: 20084918)

  • 1. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.
    Pullukcu H; Tasbakan M; Sipahi OR; Yamazhan T; Aydemir S; Ulusoy S
    Int J Antimicrob Agents; 2007 Jan; 29(1):62-5. PubMed ID: 17189097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
    Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS
    Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?
    Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E
    J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Araj GF; Jaber FA
    J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
    Oteo J; Bautista V; Lara N; Cuevas O; Arroyo M; Fernández S; Lázaro E; de Abajo FJ; Campos J;
    J Antimicrob Chemother; 2010 Nov; 65(11):2459-63. PubMed ID: 20851815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of antibiotic resistance among urine isolates of Escherichia coli in the community, despite a major hospital outbreak with Klebsiella pneumoniae producing CTX-M-15 in Uppsala County.
    Lindbäck H; Lindbäck J; Sylvan S; Melhus A
    Scand J Infect Dis; 2010 Apr; 42(4):243-8. PubMed ID: 20085420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
    Rodríguez-Avial C; Rodríguez-Avial I; Hernández E; Picazo JJ
    Rev Esp Quimioter; 2013 Mar; 26(1):43-6. PubMed ID: 23546462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
    Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
    Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short communication: comparison of susceptibilities of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics].
    Aykut Arca E; Karabiber N
    Mikrobiyol Bul; 2007 Jan; 41(1):115-9. PubMed ID: 17427560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.